Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies

Rhea-AI Summary

Catalyst Pharmaceuticals (NASDAQ: CPRX) has achieved a remarkable fifth place ranking on Forbes' 2025 list of America's Most Successful Mid-Cap Companies. This achievement follows their fourth-place position on Forbes' Small-Cap Companies list from the previous year, demonstrating the company's successful growth trajectory.

The ranking criteria included earnings growth, sales growth, return on equity, and total stock return over a five-year period, with greater emphasis on the most recent year's performance. Forbes' selection process involved screening over 700 companies with market values between $2 billion and $10 billion, requiring positive sales growth over 12 months and a minimum share price of $5. The data was collected as of November 27, 2024.

Companies excluded from consideration included financial institutions, REITs, utilities, partnerships, and those public for less than one year. CEO Rich Daly attributed this success to their growth and investment strategy, emphasizing their commitment to patient care and stakeholder value creation.

CORAL GABLES, Fla., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced its inclusion in Forbes' esteemed list of America's Most Successful Mid-Cap Companies for the year 2025. Catalyst has ranked an impressive fifth out of 100 companies on the list.

Last year Catalyst was ranked fourth in Forbes’ list of America’s Most Successful Small-Cap Companies, with this year’s ranking recognizing the company’s continued growth. The top 100 ranking is based on earnings growth, sales growth, return on equity and total stock return for the last five years, with more weight given to the latest year’s data in the ranking. All data is as of November 27, 2024, according to Forbes.

“Being ranked fifth on the Forbes list of America’s Most Successful Mid-Cap Companies for 2025 is a testament to the success of our growth and investment strategy,” said Rich Daly, President and Chief Executive Officer, Catalyst. “Our employees are dedicated to helping patients live healthier lives, and we look forward to continuing our efforts to create value for our employees, patients and shareholders.”

To create the list, Forbes used data from FactSet to screen more than 700 companies with a market value between $2 billion and $10 billion and only considered companies that also had positive sales growth over the past 12 months and a share price of at least $5. Financial institutions, REITs, utilities and limited partnerships were excluded, as were companies that have been public for less than one year.

About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence while actively seeking to expand its global commercial footprint through strategic partnerships. Catalyst, headquartered in Coral Gables, Fla., was recognized as one of North America's Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List.

For more information, please visit Catalyst's website at www.catalystpharma.com.

Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2023 and its subsequent filings with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

Source: Catalyst Pharmaceuticals, Inc.

FAQ

What ranking did CPRX achieve on Forbes' 2025 Mid-Cap Companies list?

Catalyst Pharmaceuticals (CPRX) ranked fifth out of 100 companies on Forbes' 2025 list of America's Most Successful Mid-Cap Companies.

How did CPRX's 2025 Mid-Cap ranking compare to their previous year's position?

In the previous year, CPRX ranked fourth on Forbes' list of America's Most Successful Small-Cap Companies, showing progression from small-cap to mid-cap status.

What were the criteria for Forbes' 2025 Mid-Cap Companies ranking?

The ranking was based on earnings growth, sales growth, return on equity, and total stock return over five years, with greater weight given to the most recent year's data.

What market value range was required for companies to be considered in Forbes' 2025 Mid-Cap list?

Companies needed to have a market value between $2 billion and $10 billion to be considered for the list.

What were the minimum requirements for CPRX to qualify for the 2025 Forbes Mid-Cap ranking?

Companies needed positive sales growth over the past 12 months and a share price of at least $5, along with meeting market value criteria.